ReviewNature reviews. Neurology2017
Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test.
Review in Nature reviews. Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Circular RNA: From non-coding regulators to functional protein encoders.Pharmaceutical science advances · 2025Review
- Microglial ApoD-induced NLRC4 inflammasome activation promotes Alzheimer's disease progression.Animal models and experimental medicine · 2025Article
- Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer's Disease, a Potential Therapeutic Target.Molecules (Basel, Switzerland) · 2024Review
- Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.Signal transduction and targeted therapy · 2024Review
- Evaluation of the Electronic Clinical Dementia Rating for Dementia Screening.JAMA network open · 2023Observational
- Task-dependent learning and memory deficits in the TgF344-AD rat model of Alzheimer's disease: three key timepoints through middle-age in females.Scientific reports · 2022Article
- Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.Journal of neurochemistry · 2021Review
- Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Article
- Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Article
- Impaired Reversal Learning in APPPS1-21 Mice in the Touchscreen Visual Discrimination Task.Frontiers in behavioral neuroscience · 2019Article
- Current state of Alzheimer's fluid biomarkers.Acta neuropathologica · 2018Review
- How random is the random forest? Random forest algorithm on the service of structural imaging biomarkers for Alzheimer's disease: from Alzheimer's disease neuroimaging initiative (ADNI) database.Neural regeneration research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28084326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.